Why the study?
Does patient weight influence the efficacy of warfarin dosing following total joint replacement?
Does patient weight influence the efficacy of warfarin dosing following total joint replacement?
Answers are grounded in this paper and cite their sources.
A patient's body weight significantly influences the response to warfarin following total joint arthroplasty, suggesting weight-based nomograms should be used to reduce subtherapeutic INR levels.
The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), including increased body weight, age, gender, end stage renal disease (ESRD), smoking, and peri-operative transfusion. Chart review identified 249 patients for study inclusion. Logistic regression (LR) was used to identify associated risk factors for a subtherapeutic INR (<1.8) on day of discharge. The majority of patients (58.6%, 146 of 249) following TJA surgery were found to have a subtherapeutic INR level (INR<1.8) at discharge (mean length of stay 2.6 days). Multivariate LR analysis found that weight greater than 180 lbs. (OR 2.08, CI 1.09, 3.98, P=0.027) was found to increase the odds of a subtherapeutic INR on day of discharge. Our results were not significant for weight 20% beyond ideal body weight, age (>65y), gender, peri-operative transfusion, smoking, ESRD or autoimmune disease. A patient's body weight influences response to warfarin following TJA. An inpatient warfarin dosing nomogram that takes into account a patient's weight should be used to reduce the risk of subtherapeutic INR levels in obese TJA patients.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: